Are you interested in biotech or do you believe a biotech ETF would be a good fit for your portfolio? Investing in ETFs is an easy way to increase the diversification of your portfolio. On our platform, you can find a wide selection of biotech ETFs.
Not every biotech ETF is the same. ETFs differ from each other in several ways, such as fund size, price, risk and underlying value. For example, they may track different companies or indices. Also, some may pay dividends and others may not.
These are the 5 most traded biotech ETFs by our clients in 2022.
|iShares Nasdaq US Biotechnology ETF USD Acc
|Invesco Nasdaq Biotech UCITS ETF Acc
|iShares Nasdaq US Biotechnology ETF USD Dist
|iShares Nasdaq Biotechnology ETF
|SPDR S&P Biotech ETF
iShares Nasdaq US Biotechnology ETF USD Acc
Invesco Nasdaq Biotech UCITS ETF Acc
iShares Nasdaq US Biotechnology ETF USD Dist
iShares Nasdaq Biotechnology Etf
SPDR S&P Biotech ETF
The information on this page is intended for informational purposes only and does not provide any recommendations or financial advice.
Exchange-traded funds (ETFs) make investing easier because they are the perfect product to quickly build a diversified portfolio. We offer a wide range of ETFs trading on 19 major exchanges. Whether you want to invest in local ETFs or global ETFs, investing opportunities are abundant. We even offer a Core Selection of ETFs for which commission costs are on the house. You only pay a €1 handling fee. Currency, connectivity or external product & spread costs may apply. The ETF Core Selection is subject to change and falls under a Fair Use Policy. Please check the ETF Core Selection before you invest. See the list here.
With our low fees and wide trading possibilities, we make investing in ETFs accessible to everyone. See a complete overview of our unprecedented rates here.Open an account
*Currency, connectivity or external product & spread costs may apply. Find out more on our fees page. The ETF Core Selection is subject to change and falls under a Fair Use Policy.
Vanguard S&P 500 UCITS ETF USD
Vanguard FTSE All-World UCITS ETF USD Dis
iShares Core MSCI World UCITS ETF USD (Acc)
ETFs, also known as trackers, are funds that follow the performance of an index, commodity, bond or composition of products. Unlike some other funds, ETFs are bought and sold on a stock exchange. Would you like to learn more about ETFs? Read our ETF article for all you need to know.Open an account
Biotech is short for biotechnology and is the sector that deals with turning biology knowledge into technological applications.
Companies that operate in the biotech sector develop new or more efficient methods of making products using biological processes. Biotech solutions are used in medicine, agriculture and various other industries.
Like pharmaceutical companies, biotech companies sometimes produce drugs. However, there is a difference between the two industries: drugs from biotech companies come from living organisms, and those from pharmaceutical companies have a chemical base.
Investing in biotech means investing in innovation, science and digital applications combined. Biotech companies produce many different products. You’ll find everything from COVID-19 treatments and flu vaccines to biodegradable plastic and living algae that purify water in this sector. A common denominator of all these different biotech companies is that they constantly innovate. This industry wants to find solutions for the future.
The share price of biotech companies can sometimes fluctuate considerably. This is a result of how biotech companies work. Anything can happen during the development phase. If a product turns out to be less effective or is rejected, the price can drop quickly. But once a product proves to be effective or is approved by regulators, the stock price can skyrocket. These price fluctuations can be easily hedged with ETFs. With a biotech ETF, you can invest in multiple biotech companies at the same time. This way, you can spread the risk and any price fluctuations of one company have less effect on your overall portfolio.
Biotech companies are complex and challenging due to the multitude of factors an investor must consider. ETFs that are more specific, such as biotech ETFs, compared to those that are broader, such as world ETFs, the performance will depend more on the specific sector or industry the ETF tracks.
We've been recognised as one of the best brokers in Europe thanks to our low fees, customer service and innovative platform and app.
Cash Cow 2023
Best Low-Cost Stockbroker
FT & IC 2022
Fairest online broker
Investing involves risks. You can lose (a part of) your invested funds. We advise you to only invest in financial products which match your knowledge and experience. This is not investment advice.
Investing involves risks.
We want to empower people to become the best investors they can be. By offering a universe of possibilities and choices on our user-friendly platform, we are removing barriers to make investing accessible to everyone: beginners or experts. You get access to a wide variety of products on more than 50 global exchanges to have the freedom to invest the way you like. In our world, you also get great value for money. So, without compromising an inch on the quality, security and range of our investment services, we offer incredibly low fees. Prioritising your needs has helped us become the leading European online broker. Our 2.5+ million clients and 100+ international awards are proof of our success.
Terms and conditions for the €100 transaction fees offer
If you activate your DEGIRO investment account before the 1st of March 2024, DEGIRO will reimburse your transaction fees up to €100. The following conditions apply to this offer:
Acceptance of offer conditions
By participating in the offer, the client automatically accepts the offer conditions and terms. DEGIRO may terminate the campaign at any moment prior to expiry or change the campaign conditions. DEGIRO will communicate any changes via the website.
Participation in the offer is open to all clients who have activated an account at DEGIRO on or before the 29th of February 2024.